Insights on the Antibody Drug Conjugates Global Market to 2030 - Featuring 6 Dimensions Capital, AbbVie and ABL Bio Among OthersOct 8, 2021
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific AntibodyAug 4, 2021
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific AntibodyJul 9, 2021
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid TumorsMar 30, 2021